Ameritas Investment Partners Inc. Takes Position in Zymergen Inc. (NASDAQ:ZY)

Ameritas Investment Partners Inc. bought a new stake in shares of Zymergen Inc. (NASDAQ:ZY) during the second quarter, Holdings Channel.com reports. The fund bought 1,468 shares of the company’s stock, valued at approximately $59,000.

Other large investors have also bought and sold shares of the company. Baillie Gifford & Co. acquired a new stake in Zymergen in the 2nd quarter worth about $112,906,000. ARK Investment Management LLC acquired a new stake in Zymergen in the 2nd quarter worth about $43,939,000. Russell Investments Group Ltd. acquired a new stake in Zymergen in the 2nd quarter worth about $4,495,000. New York State Common Retirement Fund acquired a new stake in Zymergen in the 2nd quarter worth about $2,835,000. Finally, Rhumbline Advisers acquired a new stake in Zymergen in the 2nd quarter worth about $841,000. Hedge funds and other institutional investors own 51.00% of the company’s stock.

Several research firms recently issued reports on ZY. William Blair cut Zymergen from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 4th. JPMorgan Chase & Co. cut Zymergen from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Wednesday, August 4th. UBS Group cut Zymergen from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $56.00 to $13.00 in a report on Tuesday, August 31st. Citigroup cut Zymergen from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $43.00 to $7.00 in a report on Wednesday, August 4th. Finally, Cowen cut Zymergen from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 4th. Three equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company. According to data from MarketBeat, Zymergen currently has an average rating of “Hold” and an average target price of $9.83.

ZY stock opened at $13.75 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.59 and a current ratio of 11.71. The firm’s 50 day moving average price is $20.82. Zymergen Inc. has a one year low of $7.85 and a one year high of $52.00.

Zymergen Company Profile

Zymergen Inc designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals.

Featured Article: Depreciation

Want to see what other hedge funds are holding ZY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymergen Inc. (NASDAQ:ZY).

Institutional Ownership by Quarter for Zymergen (NASDAQ:ZY)

Receive News & Ratings for Zymergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymergen and related companies with MarketBeat.com's FREE daily email newsletter.